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Abstract 
Background: There is an unmet need for noninvasive markers specific for kidney transplant rejection. Such a marker 
may eventually overcome the need for a transplant biopsy. In this pilot study, the potential of circulating cell‑free 
nucleosomes (CCFN) to serve as a biomarker for kidney transplant rejection was evaluated.
Methods: Forty de novo kidney transplant recipients were prospectively followed as part of a randomized, controlled 
clinical trial. Total CCFN (H3) and CCFN with the histone modifications H3K36me3 and H3 citrulline were measured in 
patients at four fixed time points: before transplantation and on days 3–6, 30 and 180 after kidney transplantation. In 
addition, serum collected at times of transplant rejection (n = 14) was analyzed. CCFN were measured with a Nu.Q™ 
Assay kit (VolitionRx), an ELISA‑based assay using antibodies directed against nucleosomes.
Results: For total CCFN (H3), H3K36me3, and H3 citrulline, the same pattern was seen over time: Concentrations 
were elevated shortly after transplantation (day 3–6) followed by a decline reaching baseline (pre‑transplantation) 
values at days 30 and 180. At times of acute rejection, the median concentration of total CCFN (H3) was significantly 
higher compared to the stable situation (day 30): 4309 (3435–5285) versus 2885 (1668–3923) ng/mL, p < 0.05, respec‑
tively. Total CCFN (H3) had an acceptable ability to discriminate rejection from no rejection (AUC‑ROC = 0.73) with a 
negative predictive value of 92.9%. For both histone modifications (H3K36me3 and H3 citrulline), there was no signifi‑
cant difference between episodes of acute rejection and the stable situation (day 30).
Conclusion: In this pilot study, total CCFN (H3) concentrations are increased at times of acute kidney transplant 
rejection. The high negative predictive value implies that whenever a patient experiences loss of renal transplant 
function and the total CCFN (H3) is not increased, causes other than acute rejection should be considered. Clinical 
implementation of total CCFN (H3) measurement may avoid unnecessary and potentially harmful kidney transplant 
biopsies.
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Background
Approximately 10–20% of kidney transplant recipients 
experiences acute rejection (AR) within the first year 
after transplantation [1]. Rejection is associated with an 
increased risk of (long-term) graft failure and death and 
accurate and timely diagnosis of acute rejection is impor-
tant to start anti-rejection therapy as soon as possible [2].
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The current diagnosis of acute rejection relies on 
serial monitoring of serum creatinine, urinary protein 
excretion and histopathological examination of a needle 
biopsy of the allograft. However, these parameters have 
several limitations. Serum creatinine is relatively insen-
sitive to diagnose rejection; a rise in serum creatinine 
occurs after substantial kidney tissue injury has occurred 
[3]. In addition, other causes of graft injury, such as infec-
tion and drug toxicity, can also lead to increased serum 
creatinine concentrations or increased urinary protein 
loss. A needle biopsy to confirm acute rejection is, how-
ever, an invasive procedure, has high costs, suffers from 
sampling error, has a relatively long turnaround time, and 
is subject to inter-observer variability [4]. In addition, a 
kidney transplant biopsy is not always feasible, for exam-
ple, in patients that require anticoagulant therapy and 
young children [5]. Therefore, there is an unmet need for 
reliable and minimally invasive biomarkers to diagnose 
kidney transplant rejection [6]. A candidate biomarker 
should be cost-effective, give reproducible outcomes, 
have a short turnaround time, and have a high sensitiv-
ity, specificity and positive and negative predictive value. 
Currently, several biomarkers are under investigation, 
including biomarkers that reflect injury to the allograft 
(for example, donor-derived cell-free DNA, kidney injury 
molecule 1, and neutrophil gelatinase-associated lipoca-
lin) [6–10]. Investigation of other potential biomarkers, 
including nucleosomes, is necessary as the diagnostic 
performance of the proposed biomarkers to replace the 
current diagnostic measures is unclear.
As a result of cell damage, nucleosomes (internal cel-
lular content) are released in the circulation, so-called 
circulating cell-free nucleosomes (CCFN). Nucleosomes 
consist of DNA wrapped around histone proteins and 
are critically involved in the epigenetic regulation of gene 
expression (6). Histone modifications, such as methyla-
tion, acetylation, ubiquitination, and phosphorylation, 
mark the “tail” domains of histones. These modifications 
alter the affinity of histone proteins for DNA and thereby 
control the transcription of genes [11]. Variation in the 
epigenetic signature of histones determines their cell-
specific phenotype and enables discrimination between 
normal and pathological cells. Total CCFN concentration 
is increased during several diseases, which make their 
use as specific biomarker for disease limited [12]. How-
ever, specific histone modifications (or combination of 
these modifications) may allow discrimination between 
diseases, such as cancer, and normal physiology [13]. In 
pancreatic cancer patients, combination of the measure-
ment of a DNA modification (5-Methylcytosine) and his-
tone modifications (H2AZ, H2A1.1 and H3K4Me2) with 
the conventionally used biomarker carbohydrate antigen 
19-9 gave a better diagnostic performance for detecting 
pancreatic cancer than the measurement of carbohydrate 
antigen 19-9 alone [14]. In the context of acute kidney 
transplant rejection, serial CCFN values may change as a 
result of the rejection process. As total nucleosome con-
centrations generally reflect cell damage, specific nucleo-
some modifications could serve as markers specific for 
kidney rejection. Citrullination of histone H3 (H3 citrul-
line) has been associated with inflammation and with the 
activation and release of neutrophil extracellular traps 
(NETs) [15, 16]. Torres-Ruiz et  al. showed that these 
NETs play a role in kidney transplant rejection; higher 
amounts of circulating NETs were found in patients 
with AR [17]. Therefore, CCFN with H3 citrulline could 
be a valuable marker in terms of AR. H3K36me3 has 
been associated with various types of malignant tumors; 
altered levels of H3K36me3 have been reported in breast 
cancer, gliomas and renal cell carcinoma [18–20]. Up 
until now, only associations has been made with renal 
cell carcinoma, and not with other types of pathology 
of kidney tissue. In the present pilot study, we investi-
gated whether total CCFN (H3) and CCFN with specific 
histone modifications (H3K36me3 and H3 citrulline) in 
serum of kidney transplant recipients could serve as a 
biomarker for acute kidney transplant rejection.
Results
Study design
This study comprised serum samples (n = 156) from 40 
kidney transplant recipients which were collected at the 
following time points: 1  day before transplantation and 
at day 3–6, 30 and 180 after transplantation and at the 
time of a clinically indicated transplant biopsy (Fig.  1). 
The baseline characteristics and clinical information after 
transplantation of these patients are depicted in Table 1. 
A total of 14 serum samples were measured from biopsy-
proven acute rejection episodes, occurring in 11 patients 
(two patients suffered from 2 or 3 episodes of biopsy-
proven acute rejection). Total CCFN (H3) and CCFN 
with the modifications H3K36me3 and H3 citrulline were 
separately investigated, and dependent on these meas-
ured epigenetic features, 1–8 samples were excluded 
because of technical failure.
Longitudinal analysis of CCFN
The values of CCFN of all patients were compared 
over time at the scheduled time points, except of val-
ues measured at times of AR (Fig.  2). For total CCFN 
(H3), H3K36me3, and H3 citrulline, the same pattern 
was seen: elevated values shortly after transplantation 
(day 3–6), followed by a decline and return to baseline 
values at day 30 and day 180. For total CCFN (H3), the 
median concentration before transplantation was 3634 
(2737–4438) ng/mL serum (Fig.  2a). Total CCFN (H3) 
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concentrations were significantly higher at day 3–6; 4535 
(3746–6170) ng/mL (p < 0.001). Thereafter, the concen-
trations returned to baseline: 2885 (1668–3923) and 2921 
(1739–4112) ng/mL for day 30 and day 180, respectively 
(p < 0.001).
For H3K36me3, the median OD before transplantation 
was 1.04 (0.78–1.43) which increased to 2.43 (1.46–3.27) 
at day 3–6 (p < 0.001) (Fig.  2b). Compared to day 3–6, 
the OD decreased to 0.71 (0.43–1.44) at day 30 and 0.97 
(0.62–1.65) at day 180, respectively (p < 0.001). For the 
modification H3 citrulline, the median OD before trans-
plantation was 1.01 (0.60–1.60) compared to 1.21 (0.56–
2.53) in day 3–6 specimens (p = ns) (Fig. 2c). Compared 
to day 3–6, the OD decreased at days 30 and 180 to 0.48 
(0.30–1.32) and 0.76 (0.39–1.10), respectively (p < 0.001).
CCFN and kidney transplant rejection
Next, CCFN values during AR were studied. To this 
end, samples with AR were compared to stable sam-
ples without AR (collected at day 30). During AR, the 
median concentration of total CCFN (H3) was with 4309 
(3435–5285) ng/mL significantly higher compared to 
2885 (1668–3923) ng/mL in samples without AR (Fig. 3a; 
p < 0.05). These results demonstrate an increase of 49.4% 
at times of AR compared to the stable situation.
For both histone modifications, no significant differ-
ences were found between samples with AR and stable 
samples without AR. For H3K36me3, the median OD 
at times of AR was 1.21 (0.95–1.72), compared to 0.87 
(0.56–1.50) during no AR (p = ns) (Fig. 3b). For H3 citrul-
line, the median OD at times of AR and no AR were 0.60 
(0.29–1.57) and 0.67 (0.32–1.16), respectively (p = ns) 
(Fig. 3c).
Next, the performance of total CCFN (H3) to discrimi-
nate AR from samples without AR was investigated by an 
AUC-ROC analysis. An AUC of 0.73 (95%-CI, 0.62–0.85; 
Fig. 4a) was calculated, showing a 69.0% sensitivity (95%-
CI, 50.8–82.7) and 71.4% specificity (95%-CI, 45.4–88.3) 
with a cutoff of 3687 ng/mL, to discriminate AR from no 
AR (Fig. 4b). The corresponding PPV and NPV for total 
Fig. 1 Overview of the study and sampling. The gray lines represent samples collected at times of AR. AR, acute rejection
Table 1 Baseline characteristics (at time of transplantation) 
and clinical information
Continuous variables are presented as medians (including ranges) and 
categorical variables as numbers (including percentages). Baseline 
characteristics and clinical information are adapted from de Graav et al. [21]
Study group (n = 20)
Age, y 54 (21–76)
Male/Female 30 (75%)/10 (25%)
Etnicity
 Caucasian 33 (82.5%)
 African 4 (10%)
 Asian 3 (7.5%)
Cause of end‑stage renal disease
 Diabetes mellitus 10 (25%)
 Hypertension 7 (17.5%)
 IgA nephropathy 4 (10%)
 Polycystic kidney disease 6 (15%)
 Obstructive nephropathy 4 (10%)
 Unknown 5 (12.5%)
 Other 4 (10%)
Renal replacement
 Preemptive/ non‑preemptive 18 (45%)/22 (55%)
No. Kidney transplantation
 First 39 (97.5%)
 Second 1 (2.5%)
 Living donor/deceased donor 40 (100%)/0 (0%)
Immunosuppressive therapy
 Belatacept based 20 (50%)
 Tacrolimus based 20 (50%)
 Biopsy‑proven acute rejection (BPAR) 11 (27.5%)
 Time to first BPAR (within the first 6 months 
after transplantation), days
56 (3–152)
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CCFN (H3), based on an incidence of AR of 15%, were 
29.9% and 92.9%, respectively.
Discussion
This pilot study was designed to investigate the potential 
of CCFN as a biomarker for the detection of acute rejec-
tion after kidney transplantation. The main finding is that 
total CCFN (H3) concentrations are increased at times 
of acute rejection compared to no acute rejection. For 
H3K36me3 and H3 citrulline, no significant differences 
were found between episodes of rejection and no rejec-
tion. Total CCFN (H3) had an acceptable ability to dis-
criminate rejection from no rejection. In particular, the 
NPV of total CCFN (H3) is high. This means that this test 
can potentially avoid a risky and costly kidney transplant 
biopsy in a patient with a deterioration of kidney func-
tion. This may result in fewer biopsy-related complica-
tions such as (life-threatening) bleeding or the formation 
of arteriovenous fistula [4]. Monitoring CCFN concentra-
tions can especially be beneficial in patients who cannot 
undergo a biopsy (as a result of the need to continue anti-
coagulant therapy) or in small children who require gen-
eral anesthesia when performing a biopsy. Finally, CCFN 
monitoring can help to reduce the number of trans-
plant biopsies in patients with potentially more harmful 
biopsy-related complications, such as in cardiac trans-
plant recipients.
In contrast to the high NPV, the low PPV for total 
CCFN (H3) is an obvious limitation. However, we feel 
that even when the PPV of total CCFN (H3) would have 
been higher, this still would not circumvent the need for 
a biopsy. A biopsy is not only necessary to demonstrate 
acute rejection but also discriminates different rejection 
types which require different therapies [22, 23].
The present findings demonstrate that both histone 
modifications are not associated with acute rejection in 
kidney transplant recipients. Nevertheless, it could still 
be possible to increase the specificity of nucleosomes as 
a marker for kidney transplant rejection by measuring 
other nucleosome modifications.
Fig. 2 Course of CCFN values in 40 kidney transplant recipients (a). Depicted are the concentrations of total CCFN (H3) and ODs of b CCFN with 
H3K36me3 and c CCFN with H3 citrulline over time. OD, optical density. N.B.: CCFN box whiskers represent minimal and maximal values. The middle 
line of the box represents the median and the upper and lower borders represent the 25 and 75% percentile, respectively (*p < 0.05, **p < 0.01, 
***p < 0.001)
Fig. 3 CCFN values at times of AR compared to the stable situation (day 30). a Concentrations of total CCFN (H3) and b ODs of CCFN with 
H3K36me3 and c H3 citrulline. OD, optical density. The middle line of the box represents the median and the upper and lower borders represent the 
25 and 75% percentile, respectively (*p < 0.05, **p < 0.01, ***p < 0.001)
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Another finding of this study was that CCFN values 
change over time. Both total CCFN (H3) and CCFN 
with H3K36me3 were significantly higher shortly after 
transplantation (day 3–6) and total CCFN (H3) and both 
modifications (H3K36me3 and H3 citrulline) decreased 
significantly at the day 30 and day 180 time points. 
Increased values shortly after transplantation have also 
been observed for other potential biomarkers for acute 
rejection, such as circulating cell-free DNA [6, 24]. We 
speculate that ischemia and repair and regeneration 
processes (accompanying kidney transplantation) that 
results in ischemia–reperfusion injury (IRI), leads to 
increased CCFN values shortly after transplantation due 
to cellular apoptosis and necrosis [25].
Despite the relatively few rejection events (n = 14), lim-
iting the statistical power of this study, significant differ-
ences were observed. Three of these rejections occurred 
at day 3–6 after transplantation when CCFN may have 
increased as a result of IRI. Currently, we are collecting 
samples in a larger cohort of kidney transplant recipients 
where the effect of IRI on CCFN during rejection should 
be explored by comparing rejections occurring shortly 
after transplantation with rejections occurring later 
on after transplantation. It would also be of interest to 
investigate CCFN using ImageStream(X)-based imaging 
technology, a newly identified promising methodological 
approach to measure CCFN [26].
The rejections in this study were all biopsy-proven, 
whereas the no rejection samples were not. This means 
that within the no rejection group, serum samples may 
have been collected at times of a subclinical rejection, 
which by definition, can only be detected by protocol 
biopsy as patients with a subclinical rejection do not have 
clinical graft dysfunction. To rule out the possible effect 
of subclinical rejection, it would be preferable to perform 
protocol biopsies, which allows for the comparison of 
biopsy-proven rejection samples with biopsy-confirmed 
no rejection samples.
An advantage of CCFN is that the measurement can be 
performed within hours, requires very small amounts of 
sample volume (10  µL), and that large variety of differ-
ent measurable histone modifications are available [14]. 
This large variety allows for the epigenetic profiling of 
CCFN to identify specific combinations of epigenetic 
features which can be used to improve the diagnostic 
performance of CCFN to serve as a marker for acute 
rejection. It would be interesting to assess the discrimina-
tory capacity of CCFN to differentiate between different 
types of acute rejection and between rejection and other 
types of pathology such as acute tubular necrosis, BK 
virus nephropathy, pyelonephritis and renal calcineurin 
inhibitor toxicity.
Conclusion
Analysis of CCFN concentrations in serum of kidney 
transplant recipients is a promising minimally invasive 
diagnostic tool to screen for acute rejection after kidney 
transplantation. Measurement of total CCFN (H3) has a 
high negative predictive value for acute rejection. These 
findings suggest that whenever a patient experiences loss 
of renal transplant function and CCFN is not increased, 
causes other than acute rejection should be considered. 
Clinical implementation of CCFN measurement may 
avoid unnecessary and potentially harmful transplant 
biopsies.
Fig. 4 Diagnostic performance of total CCFN (H3) to discriminate from the stable situation (day 30 and day 180). a ROC curve and b. Sensitivity 
(black) and specificity (white) depicted over the observed range of CCFN concentrations. Reported sensitivity and specificity correspond to a cutoff 
of 3687 ng/mL serum. PPV and NPV are based on an incidence of AR of 15%. AUC, area under the curve; PPV, positive predictive value; NPV, negative 
predictive value
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Methods
Patient population and samples
Serum samples were collected from 40 kidney transplant 
recipients who participated in an investigator-initiated, 
prospective, randomized-controlled, single-center, clini-
cal trial performed at the Erasmus MC, University Medi-
cal Center, Rotterdam, the Netherlands [21]. The study 
was approved by the Medical Ethical Review Board 
(MERB number METC-2012-421) and was registered in 
the Dutch national trial registry (https ://www.trial regis 
ter.nl/trial s; number NTR4242, registered October 2013). 
All participating patients gave written informed consent 
before inclusion. Samples were collected at the following 
time points: 1 day before transplantation and at day 3–6, 
30, and 180 after transplantation and at the time of a clin-
ically indicated transplant biopsy (collected 4 days before, 
till 1 day after the biopsy) (Fig.  1). Only serum samples 
of patients who were diagnosed with biopsy-proven acute 
rejection (as opposed to other histopathological diagno-
ses) were analyzed. No protocol biopsies were obtained 
in this trial.
The serum samples were centrifuged (1910 g, 10 min) 
and the supernatant was stored at − 80  °C until further 
use. All biopsies were scored independently by two expe-
rienced kidney pathologists according to the Banff 2015 
classification [27]. At the time of the trial, donor-specific 
anti-HLA antibodies were not routinely measured and 
therefore the biopsies could not be scored according to 
the most recent Banff classification [28].
Cell‑free nucleosome immunoassays
Total CCFN (histone H3) and CCFN with the modifi-
cations H3K36me3 (commonly altered in several can-
cer types) and H3 citrulline (induced in neutrophils in 
response to inflammatory stimuli) were separately meas-
ured by the manufacturer using a not commercialized 
NuQ® ELISA (Belgian Volition SPRL, Isnes, Belgium) 
according to the manufacturer’s instructions [14, 29]. 
The ELISA assays used were sandwich ELISA’s where 
(1) the capture antibody consisted of an antibody raised 
again either a histone H3 epitope for the quantification 
of CCFN (H3) or against H3K36Me3 or H3 citrulline, for 
the two nucleosome modification assays, respectively; 
(2) the detection antibody was a biotinylated anti-nucle-
osome detection antibody directed against a nucleo-
some conformational epitope (which confirms that 
nucleosomes were measured and not histones). In brief, 
96-well microtiter plates were coated with a capture anti-
body and 10 μL of serum was dispensed into each well 
(in duplicate). After incubation for 150  min, the bioti-
nylated anti-nucleosome antibody solution was added to 
each well and the plate was incubated for another 90 min. 
Wells were then washed with a wash buffer (provided by 
Volition), a streptavidin–horseradish peroxidase solu-
tion was added and the plate was incubated for 30 min. 
Subsequently, wells were washed, substrate solution was 
added and after 10–20 min, the colorimetric reaction was 
stopped by adding the diluted stop solution (provided 
by Volition). All incubation steps were performed at 
15–25 °C with orbital shaking at approximately 700 rpm. 
The optical density (OD) of the wells was determined 
with a spectrophotometer at 405  nm. For both histone 
modifications, values were expressed as OD units, while 
for the total CCFN (H3) values were expressed as con-
centration (ng/mL serum).
Statistical analysis
All analyses were performed using GraphPad (5.01, 
GraphPad, Inc, LA Jolla, CA) and SPSS version 25.0 (IBM 
Corp., Armonk, NY, USA). Continuous variables are 
reported as median and inter-quartile range (IQR; first 
and third quartiles). To evaluate CCFN values over time, 
samples at different time points from the same patients 
were compared using a linear mixed model with a ran-
dom intercept for patient to adjust for repeated measure-
ments within patients.
To evaluate the performance of CCFN as a biomarker 
for acute kidney transplant rejection, samples were 
divided into an AR group and a non-AR group. The non-
AR group consisted of day 30 samples of clinically sta-
ble patients who were free from (biopsy-proven) AR at 
this time point, or from other causes of (histologically 
confirmed) allograft injury. The AR group consisted of 
samples of patients with biopsy-proven rejection. In 
this group, all samples collected from different rejection 
events were used for the analysis. Differences between 
the AR measurements and non-AR measurements were 
compared using a linear mixed model with a random 
intercept for patient to adjust for multiple measurements 
per patient.
The area under the curve–receiver operating character-
istic curve (AUC-ROC) was used to assess the discrimi-
native ability of total CCFN (H3) for differentiating AR 
and non-AR. Based on a data-driven cutoff value, sensi-
tivity and specificity were calculated. The positive predic-
tive value (PPV) and negative predictive value (NPV) for 
AR were calculated based on an assumed incidence of 
AR of 15%.The 95% confidence intervals of the AUC were 
estimated using bootstrapping. All statistical tests were 
considered statistically significant when the two-sided 
p value was below 0.05.
Abbreviations
AR: Acute rejection; AUC‑ROC: Area under the curve‑receiver operating char‑
acteristic; BPAR: Biopsy‑proven acute rejection; NETs: Neutrophil extracellular 
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traps; CCFN: Circulating cell‑free nucleosomes; NPV: Negative predictive value; 
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